Healthcare provider profile · identity verified

Javier Yulfo Ramos, MD

General Practice · AGUADA, PR · NPI 1346569019

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	356	48
Losartan Potassium	Losartan Potassium	317	38
Simvastatin	Simvastatin	314	38
Atorvastatin Calcium	Atorvastatin Calcium	255	37
Amlodipine Besylate	Amlodipine Besylate	226	31
Metformin Hcl	Metformin Hcl	190	24
Glimepiride	Glimepiride	177	20
Levothyroxine Sodium	Levothyroxine Sodium	177	25
Lisinopril	Lisinopril	176	22
Famotidine	Famotidine	164	33
Tamsulosin Hcl	Tamsulosin Hcl	161	21
Hydrochlorothiazide	Hydrochlorothiazide	158	18
Clopidogrel	Clopidogrel Bisulfate	133	18
Pantoprazole Sodium	Pantoprazole Sodium	107	24
Montelukast Sodium	Montelukast Sodium	103	15
Synthroid	Levothyroxine Sodium	99	11
Diclofenac Potassium	Diclofenac Potassium	98	74
Memantine Hcl	Memantine Hcl	89	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	84	11
Prednisone	Prednisone	75	66
Alendronate Sodium	Alendronate Sodium	74	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	74	suppressed
Carvedilol	Carvedilol	73	14
Metoprolol Succinate	Metoprolol Succinate	73	suppressed
Atenolol	Atenolol	72	suppressed
Azithromycin	Azithromycin	71	58
Baclofen	Baclofen	70	57
Donepezil Hcl	Donepezil Hcl	65	14
Albuterol Sulfate Hfa	Albuterol Sulfate	63	suppressed
Sertraline Hcl	Sertraline Hcl	61	13
Escitalopram Oxalate	Escitalopram Oxalate	59	suppressed
Mirtazapine	Mirtazapine	59	suppressed
Meloxicam	Meloxicam	57	11
Glipizide	Glipizide	56	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	56	suppressed
Latanoprost	Latanoprost	55	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	55	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	53	suppressed
Levetiracetam	Levetiracetam	52	suppressed
Citalopram Hbr	Citalopram Hydrobromide	50	suppressed
Hydralazine Hcl	Hydralazine Hcl	49	suppressed
Trazodone Hcl	Trazodone Hcl	49	suppressed
Eliquis	Apixaban	47	suppressed
Furosemide	Furosemide	46	suppressed
Clonazepam	Clonazepam	45	17
Enalapril Maleate	Enalapril Maleate	44	suppressed
Buspirone Hcl	Buspirone Hcl	42	suppressed
Omeprazole	Omeprazole	42	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	40	suppressed
Cephalexin	Cephalexin	38	36
Quetiapine Fumarate	Quetiapine Fumarate	38	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	38	15
Cilostazol	Cilostazol	37	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Nifedipine Er	Nifedipine	36	suppressed
Theophylline Er	Theophylline Anhydrous	36	suppressed
Tramadol Hcl	Tramadol Hcl	36	15
Finasteride	Finasteride	34	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	30	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	30	suppressed
Verapamil Er	Verapamil Hcl	30	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	26	suppressed
Ramipril	Ramipril	26	suppressed
Nabumetone	Nabumetone	25	14
Alprazolam	Alprazolam	24	suppressed
Irbesartan	Irbesartan	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	24
Methotrexate	Methotrexate Sodium	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Aripiprazole	Aripiprazole	22	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Jardiance	Empagliflozin	22	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	20	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Metronidazole	Metronidazole	18	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	18	18
Sucralfate	Sucralfate	18	suppressed
Digoxin	Digoxin	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Rivastigmine	Rivastigmine	17	suppressed
Megestrol Acetate	Megestrol Acetate	16	suppressed
Olanzapine	Olanzapine	16	suppressed
Temazepam	Temazepam	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Glipizide Er	Glipizide	14	suppressed
Humalog	Insulin Lispro	14	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Levofloxacin	Levofloxacin	14	13
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Anastrozole	Anastrozole	13	suppressed
Bumetanide	Bumetanide	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Jentadueto	Linagliptin/Metformin Hcl	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Levetiracetam Er	Levetiracetam	11	suppressed
Novolin R	Insulin Regular, Human	11	suppressed
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error